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Diabetes mellitus (DM) is a metabolic disease in which indi-
viduals have elevated blood glucose levels. DM is a current global 
health problem impacting children, adolescents, and adults. The 
World Health Organization (WHO) has reported that 347 million 
people worldwide suffer from diabetes, with about 3.4 million 
people dying in 2004 due to consequences of high fasting blood 
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ABSTRACT
Diabetes is a major concern among medical practitioners, with the annual mortality rate increasing up to 26.9% in a person aged 65 
years or older and 11.3% in the adult. There are many serious complications associated with diabetes, particularly cardiovascular 
complications due to microvascular diseases. A prerequisite to reduce the risk of microvascular and neurologic complications of type 
1 diabetes is normoglycemia. Insulin therapy is the most common treatment used nowadays in type 1 diabetes. However, this method 
still has many disadvantages such as increased episode of severe hypoglycemia, hypoglycemia unawareness, increased weight gain, 
transient exacerbation of pre-existing retinopathy, etc. Using insulin pump (the insulin pump is a medical device used for continuous 
subcutaneous insulin infusion to manage the insulin level in the treatment of diabetes mellitus), is associated with known disadvantages 
including increased ketoacidosis, infection at the infusion site, and the treatment being less suitable in young children (less than 7 years 
of age). Therefore, alternative treatment for diabetes is still in great demand. We took the approach of traditional Chinese medicine 
to discuss this matter. Sesame (芝麻 Zhī Má), a herb, has been used medicinally for thousands of years in almost all the countries in 
the world. The beneficial effects of sesame in remediating diabetes, such as hypoglycemic effects, antioxidant, anti-inflammatory, and 
hypolipidemic effects, improving fat metabolism, and reducing cholesterol, have been demonstrated in many studies,. However, reports 
on the effects of sesame in remediating cardiovascular complications in diabetic patients are limited, which necessitates further studies 
on the effects of sesame on cardiovascular complications.
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glucose.[1] In 2030, the seventh leading cause of death globally 
will be diabetes.[2] Diabetes can lead to a variety of complications, 
including cardiovascular diseases such as ischemic heart disease, 
peripheral vascular disease, cerebrovascular disease, and many 
types of ocular disease such as retinopathy, nephropathy, and 
neuropathy[3] [Figure 1].
Cell-mediated autoimmune destruction of pancreatic islet 
beta cells causes decreased insulin production, which leads to 
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type 1 diabetes mellitus or T1DM.[4] Although only about 10% 
of world population suffers from T1DM, the risk of death from 
T1DM is high.[5,6] The current annual rate of increase in cases of 
T1DM globally is 3–5%. If this trend continues, the number of 
new cases of T1DM in European children younger than 5 years 
is predicted to double between 2005 and 2020 and rise by 70%, 
with the condition common in children younger than 15 years. In 
the United States, about 215,000 people aged 20 years or older 
are diagnosed with diabetes and the number of new cases with 
diagnosis of diabetes is about 1.9 million. It is expressed in 0.26% 
of all people in this age group.[7]
Health care and social care related to T1DM are significant 
burdens for the economy of any country.[8] In developed coun-
tries, diabetes is one of the leading causes of retinopathy, kidney 
disease, and foot problems and the main cause of deaths from 
cardiovascular disease, all of which place a heavy burden on their 
economies.[9] In addition, a study from US has shown that T1DM 
subtracts 5–20 years from a patient’s lifespan.[10] This is similar to 
the finding of a European study, which reported that when a child 
has T1DM, the standardized mortality rate (SMR) increases up to 
fourfold.[11] T1DM not only affects economies and the lifespan of 
patients, but also causes major psychological impacts, particularly 
in adolescents.[12]
The development of long-term microvascular and macrovas-
cular complications is the main cause for the increased morbidity 
and mortality related to T1DM.[9] While testing the ratio of mi-
crovascular and acute diabetes complications and the relationship 
between diabetes duration and blood glucose control, Stephenson 
and Fuller found a significant correlation between microvascular 
and acute complications and the duration of diabetes and glycemic 
control.[13] In addition, degradation of long-term control of glucose 
metabolism and blood pressure and the development of retinopa-
thy, neuropathy, and atherosclerotic complications lead to increas-
ing trends in patient mortality. These are usually simultaneously 
caused by diabetic kidney disease.[14] For example, glomerular 
basement membrane thickening, increased mesangial matrix, and 
reduced glomerular filtration surface density are caused by renal 
disease which has long been considered the worst complication 
in patients with T1DM.[15] These pathologies have been shown 
to be related to albumin excretion rate and decreased glomerular 
filtration rate, which usually occur in most patients with T1DM.[15] 
Recent studies report that the relationship between diabetes and 
cardiovascular dysfunction has become clearer and more perni-
cious.[16-18]
CARDIOVASCULAR DISEASE IN PATIENTS 
WITH TYPE 1 DIABETES
Ischemia leads to mortality rates higher than those due to 
other complications in the T1DM population at all ages. Occur-
rence of ischemia is extremely high not only in young women 
with T1DM but also in men under the age of 40.[16] In younger 
population, imaging techniques have demonstrated that children 
with T1DM are exposed to greater risk of atherosclerosis than 
children without T1DM. The leading cause of mortality in young 
patients with T1DM, i.e. nephropathy, has been replaced by car-
diovascular disease.[18]
Macrovascular complications cause damage to several or-
gans. Coronary atherosclerosis occurs in most of the diabetic 
population, and 20% of the deaths of diabetic patients are due to 
myocardial infarction. Early diastolic dysfunction and late systolic 
dysfunction are characteristics of diabetic cardiomyopathy, in 
which intracellular calcium and sodium levels are maintained but 
potassium is reduced. In addition, left ventricular hypertrophy is 
a complication related to diabetes.[19] The following are the risk 
factors related to microvascular and macrovascular complications 
in T1DM: reformative factors, including glycemic monitoring, 
hypertension, dyslipidemia, diet, sedentary lifestyle, and tobacco 
use; and non-reformative factors, including diabetes monitoring 
and duration, genes, and puberty.[17,20] Impairment in remodeling 
of microvasculature related to hyperglycemia is the main indicator 
and the main factor leading to target organ damage.[21] According 
to a recent study, 86% of young people suffering from T1DM have 
at least one risk factor for cardiovascular disease, 45% are exposed 
to at least two factors, and 15% have at least three modifiable risk 
factors related to the disease.[22]
Clinical methods for detecting vascular dysfunction can help 
experts use appropriate treatment methods to prevent the develop-
ment of complications.[20] Maintaining the blood glucose levels as 
close to normal as possible is the most effective way to manage 
diabetes. Variability in hemoglobin A1c (HbA1c) and diabetes 
duration are the modifiable risk factors closer to development of 
complications.[23,24] In another study, the authors reported a rela-
tionship between significantly increased incidence of congestive 
heart failure and higher HbA levels in individuals with diabetes.[25]
In 2008, Cheung et al.[26] reached the conclusion in their article 
that the rate of incidence of heart failure is closely related to dia-
betic retinopathy. They observed an increase in the development of 
heart failure in patients with retinopathy (cumulative incidence of 
21.6%) compared to individuals without retinopathy (cumulative 
incidence of 8.5%). 
Experts suggest that individuals with T1DM who have a strong 
family history of cardiovascular disease should practice a fasting 
lipid blood screening at 2 years of age.[27] To avoid an atherogenic 
lipoprotein profile, glycemic control is necessary, and if there is 
an abnormal lipid profile, annual monitoring is required. If the 
Figure 1. Diabetes and its complication of vascular diseases
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lipoprotein density value is greater than 4.1 mmol/l or 3.4 mmol/l 
and the individual has at least one other evident cardiovascular risk 
factor, the individual should follow a diet that restricts dietary fat to 
7% of total calories and dietary cholesterol to 200 mg/d.[28] Age of 
onset, duration, blood glucose monitoring, and cardiovascular risk 
factors affect the appearance of complications such as neuropathy, 
retinopathy, and especially renal disease.[29,30] 
Several studies have described the relationship between 
hyperglycemia and cardiovascular disease, but the relation-
ship in the setting of T1DM is still unclear and incompletely 
understood.[31,32] Moreover, psychological factors, in particular 
depressive symptomatology, are not only the leading factors in 
angina and insulin resistance but also barely predict coronary 
artery disease (CAD) – the buildup of plaque in the arteries, 
cause of atherosclerosis status, leading to the interruption of 
blood flow[33] – end points.[32]
Because the incidence of cardiovascular dysfunction in 
patients with T1DM is higher than in those without T1DM, to 
prevent heart disease with its long asymptomatic latent period, 
the estimated global risk scores for cardiovascular risk should be 
provided.[4,34] Normoglycemia is a prerequisite to reduce the risk of 
microvascular and neurologic complications related to T1DM. By 
observing the symptoms of cardiovascular disease, such as nonfatal 
myocardial infarction, stroke, death from cardiovascular disease, 
confirmed angina, or the need for coronary artery revasculariza-
tion, researchers have realized a significant percentage reduction 
in cardiovascular disease occurrence (42%, P = 0.02) and the risk 
of nonfatal myocardial infarction, stroke, or death from cardio-
vascular disease (52%, P = 0.02) in diabetic patients. In addition, 
decreasing glycosylated hemoglobin content has a positive effect 
in intensive therapy on the risk of cardiovascular disease. There 
is a close relationship between microalbuminuria and albuminuria 
and an increased risk of cardiovascular complications.[35] Intensive 
treatment, either by external insulin pump or three or more daily 
insulin injections, guided by frequent blood glucose monitoring 
improved the resistance and retarded the appearance of complica-
tions such as diabetic retinopathy, nephropathy, and neuropathy in 
patients with T1DM.[36,37] Furthermore, self-monitoring of blood 
glucose can also provide an accurate assessment of blood sugar 
levels. Results of self-monitoring blood glucose are helpful in 
preventing hypoglycemia and adjusting medication use, physical 
activity, and diet.[38] Self-monitoring has been identified as an in-
tegral part of diabetes education, and self-management of diabetes 
medical nutrition therapy is essential for patients with diabetes. 
Physical activity has been shown to cause significant improvement 
in glycemic control. It also helps in prevention of cardiovascular 
risk factors, leads to weight loss, and improves health in diabetic 
subjects.[39] Strictly controlled dietary behaviors improve diabetic 
subjects’ health status.[24] A protein-deficient diet (0.6–0.7 g/kg/d) 
minimizes the complications of diabetic nephropathy.[40] More 
than 150 min of intense physical activity per week supports the 
melioration of metabolic control.[41] Consumption of carbohydrates 
might be increased by an active lifestyle in patients who underwent 
islet cell transplantation.[42]
Supporting knowledge of diabetes is also important in reduc-
ing negative psychological impacts on the patient. A Danish study 
showed that patients with a positive view in life will have lower 
complication rates than the patients with psychosocial distress.[43] 
TRADITIONAL CHINESE MEDICINES IN 
DIABETES
Traditional Chinese medicines or functional foods are also 
positive treatments to improve the health of patients with diabetes 
status.[44-47] The pharmacological activities of herbal medicines, 
such as ameliorating insulin sensitivity, promoting insulin secre-
tion, increasing glucose uptake by adipose and muscle tissues, 
inhibiting sugar absorption in the intestines, and increasing the 
storage of sugar in the liver, have been demonstrated in many 
studies.[48,49] Moreover, traditional Chinese medicines have been 
shown to have an effective impact on the treatment of cardio-
vascular complications in diabetic patients.[50] In type 1 diabetes, 
most of the herbal in some way protect the beta cells from attack 
by the immune system. KRG extract not only protects against 
streptozotocin (STZ)-induced destruction of pancreatic tissue but 
also restores insulin secretion. Also, the histopathologic results 
showed the recovery of lymphocytes in lymphoid organs.[46] The 
herbal was a success in the fight against CD8(+) – a cytotoxic T 
cell – and inhibited infiltration of lymphocytes into islets.[46] But 
in type 2 diabetes, these receptors are encouraged to produce as 
well as increase its efficiency by the effects of herbal, thereby 
reducing the blood glucose level.[49]
Certain herbals have been demonstrated to have properties 
that can improve the health of diabetics.[51,52] Korean red ginseng 
(紅參 Hóng Shēn; Panax ginseng), one type of traditional Chinese 
medicine, has been demonstrated to ameliorate diabetes. Extracts 
of this herb reduced glycemia and simultaneously reduced STZ-
induced destruction of pancreatic tissue, while regenerating insulin 
secretion.[44] Green tea (綠茶 Lǜ Chá; Camellia sinensis) has also 
shown a positive antihyperglycemic and antioxidant activity after 
4 weeks of treatment at a dose of 200 mg/kg in STZ-induced 
rats.[53] Ginger (生薑 Shēng Jiāng; Zingiber officinale) not only 
increases glucose tolerance but also increases serum insulin lev-
els; this is likely related to participation of 5-hydroxytryptamine 
(5-HT) receptors.[54] The use of cucurbitaceae (苦瓜 Kǔ Guā; 
Momordica charantia L.) juice also showed a hypoglycemic 
effect similar to Camellia and Z. officinale, but its side effect is 
still a troubling issue and unclear.[55] Another herb, Polygonatum 
odoratum (玉竹 Yù Zhú; TFP), has also been investigated for its 
antihyperglycemic effects. Oral administration of TFP for 9 days 
lowered the blood glucose levels. Insulin level was also increased 
by TFP in type 2 diabetic rats.[56] The hypoglycemic activity of 
To-kai-san (TS) – a complex Chinese medicine – was reported 
by Miura et al.[57] TS not only exhibits hypoglycemic action but 
also decreases plasma insulin levels after 20 days of oral admin-
istration.[57] Chinese herbs, including holy basil leaves (Ocimum 
tenuiflorum), Xianzhen Pian (C. sinensis), Qidan Tongmai (a tablet 
of Chinese herbs), traditional Chinese formulae (TCT), Huoxue 
Jiangtang Pingzhi, and Inolter, exhibited significant hypoglycemic 
effects when compared with placebo. Moreover, seven herbal 
medicines, including Bushen Jiangtang Tang (a Chinese herbal 
recipe), composite Trichosanthis (瓜蔞 Guā Lóu; Trichosanthes 
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kirilowii), Jiangtang Kang, Ketang Ling, Shenqi Jiangtang Yin 
(Schisandra (五味子 Wǔ Wèi Zǐ), Astragalus (黃耆 Huáng Qí), 
Dioscorea (懷山藥 Huái Shān Yào), Rehmannia (熟地 Shóu Dì), 
Rubus Chingii Hu (覆盆子 Fù Pén Zǐ), Wolfiporia (茯苓 Fú Ling), 
Trichosanthes kirilowii, Xiaoke Tang, and Yishen Huoxue 
Tiaogan, were found to exhibit better metabolic control than the 
hypoglycemic drugs such as glibenclamide, tolbutamide, and 
gliclazide.[58] Furthermore, there have been no reports about the 
side effects from herbal medicines.[58] Most of the herbs are used 
as a mixture form.[59] So, the effect of each herb is not clear and 
this causes difficulties in the treatment of diabetes. 
BENEFITS OF SESAME IN DIABETES
Since ancient times, sesame (芝麻 Zhī Má; Sesamum) has 
been considered a rare herb that can treat or prevent diseases. 
Sesame oil has been shown to reduce the risk of cardiac hy-
pertrophy in mice with high blood pressure. Regression of left 
ventricular hypertrophy in hypertensive rats has been shown by 
its effects in reduction of cardiac mass, left ventricular thick-
ness, and cardiomyocyte diameter, showing that sesame oil can 
have a positive effect on the status of cardiac hypertrophy in 
hypertensive rats.[60] 
In recent studies, sesame and its ligands have been shown to 
have beneficial effects in treating, preventing, and ameliorating 
diabetes. The combined consumption of sesame oil and gliben-
clamide not only reduced the blood glucose levels significantly 
(36% in treatment compared to no treatment) but also decreased 
plasma total cholesterol, and this significantly improved the 
condition of subjects with type 2 diabetes.[61] Incubation of beta 
cells damaged by STZ with sesamin significantly improved cell 
viability, insulin secretion activity, activities of superoxide dis-
mutase (SOD) and glutathione peroxidase (GSHpx), and reduced 
glutathione (GSH) content. Significant reductions in malondialde-
hyde (MDA) content, nitric oxide (NO) production,  the enzyme 
activities of NO synthase (NOS), and induced NOS (iNOS) were 
observed in these cells when they were incubated with sesamin. 
The status of the damaged cells changed in a positive way. Sesamin 
can reduce beta cell-damaging factors such as oxidative stress and 
NO synthesis.[62] Hypoglycemic and hypolipidemic activity has 
been observed in KK-Ay mice, an animal model of type 2 diabetes 
and insulin resistance, when they were given sesamin orally. Such 
activity might be due to increased insulin sensitivity and improved 
insulin resistance by sesamin.[63] Blood glucose in adult female 
albino Wistar rats was significantly reduced from 322.61 ± 9.49 
mg/dl to 222.02 ± 8.27 mg/dl when they were fed with sesamin. 
Elevated levels of glycosylated hemoglobin, vitamin E, thiobarbi-
turic acid-reactive substances (TBARS), and lipid hydroperoxides 
were found to decrease on administration of sesamin. In contrast, 
the levels of hemoglobin, vitamin C, and GSH increased on oral 
administration of sesamin.[64]
Other than the cardiovascular system, sesame also demon-
strates benefits in other systems. Bone loss due to estrogen defi-
ciency was reduced by oral administration of diets supplemented 
with soybean oil and sesame oil in ovariectomized rats.[65] Sesame 
oil and sesamol have also exhibited effectiveness in treating heavy 
metal poisoning.[66] Concentrations of vitamins E and K increased 
in rat tissue on using sesame seeds and ligands as the main diet.[67] 
In another study on the inhibition of systemic IgE levels in al-
lergic asthma, sesame oil reduced pulmonary edema and neutral 
bronchitis; meanwhile the interleukin (IL)-1β and IL-6 levels 
were significantly decreased in bronchoalveolar lavage fluid.[68]
Sesamin is the active agent and one of the most abundant 
lignans in sesame. It exhibits a variety of actions and functions, 
and is of much value as a pharmaceutical.[69] Numerous studies 
have demonstrated that sesamin has numerous health benefits, 
including improvement in fat metabolism, antioxidant action, hy-
polipidemic activity, reduction of cholesterol, anti-inflammatory 
action, enhanced potency of vitamin E, etc.[69]
CONCLUSIONS
Surpassing nephropathy, cardiovascular diseases have become 
the most serious complications resulting in high morbidity and 
mortality rates in diabetic subjects. Microvascular abnormalities 
in diabetes cause cardiovascular complications. To minimize these 
complications, detecting early onset of microvascular disease is 
essential. In addition, other risk factors associated with macrovas-
cular diseases such as diabetic nephropathy, diabetic retinopathy, 
and diabetic neuropathy require attention during disease process 
monitoring.[70] Numerous studies have provided a variety of meth-
ods for improving the diabetes status and related complications, 
including intensive treatment, pumping and injecting insulin, 
hypoglycemia drugs, and placebos.[36,37] A current interest is the 
application of natural medicines in disease treatment to limit the 
adverse effects of chemical drugs. Traditional Chinese medicines 
have a role in such treatments, especially in diabetes.[57] Sesame 
(芝麻 Zhī Má) has long been regarded as a precious herb. Effects 
of sesame in reducing glycemia and improving the diabetes status 
and its complications have long been demonstrated. However, few 
reports suggest that sesame can aid in improving cardiovascular 
complications in diabetic patients, and therefore necessitates 
further research [Figure 2].
Figure 2. Overview of type 1 diabetes research
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